Evidence map›Paper›PMID 32552264›Full record

Trial reportJournal of the American Heart Association2020

Extended-Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction.

Shane Nanayakkara, Melissa Byrne, Vivian Mak, Kaye Carter, Eliza Dean, David M Kaye

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Article
  8. Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. A Holistic View of Advanced Heart Failure.Life (Basel, Switzerland) · 2022
    Review
  14. Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Shane NanayakkaraDepartment of Cardiology Alfred Hospital Melbourne Australia.
Melissa ByrneHeart Failure Research Group Baker Heart and Diabetes Institute Melbourne Australia.
Vivian MakDepartment of Cardiology Alfred Hospital Melbourne Australia.
Kaye CarterDepartment of Cardiology Alfred Hospital Melbourne Australia.
Eliza DeanDepartment of Cardiology Alfred Hospital Melbourne Australia.
David M KayeDepartment of Cardiology Alfred Hospital Melbourne Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent form of heart failure, representing half of the total burden of heart failure. We hypothesised that modulation of the phosphodiesterase type 3/cyclic AMP using a novel oral formulation of milrinone might exert favorable effects HFpEF via pulmonary and systemic vasodilation and enhancement of ventricular relaxation. We assessed the safety and efficacy of oral milrinone on quality of life and functional outcomes in patients with HFpEF. Methods and Results The MilHFPEF (Extended Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction) study was a randomized, double-blind, placebo-controlled pilot study in 23 patients with symptomatic HFpEF. Efficacy end points included changes from baseline in Kansas City Cardiomyopathy Questionnaire summary score and 6-minute walk distance. The primary safety end point was the development of clinically significant arrhythmia. The Kansas City Cardiomyopathy Questionnaire score improved significantly in milrinone-treated patients compared with placebo (+10±13 versus -3±15;

Indexed as

Administration, OralAgedAged, 80 and overDelayed-Action PreparationsDouble-Blind MethodExercise ToleranceFemaleHealth StatusHeart FailureHumansMaleMilrinonePhosphodiesterase 3 InhibitorsPilot ProjectsProspective StudiesQuality of LifeDelayed-Action PreparationsMilrinonePhosphodiesterase 3 Inhibitorsdiastolic heart failureinotropeslusitropypharmacotherapyphosphodiesterase type 3

Identifiers

PMID32552264
PMCPMC7670502

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.